
    
      To assess the efficacy and safety of efficacy of MTS compared to placebo, as determined by
      the change in the clinician completed ADHD Rating Scale - Version 4th Edition (ADHD-RS-IV),
      in the symptomatic treatment of adolescents (aged 13-17 years) diagnosed with ADHD.
    
  